JARISLOWSKY FRASER Ltd Has $140.30 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

JARISLOWSKY FRASER Ltd decreased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 719,874 shares of the medical research company's stock after selling 30,382 shares during the period. JARISLOWSKY FRASER Ltd owned approximately 0.40% of IQVIA worth $140,301,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in IQV. Norges Bank bought a new stake in shares of IQVIA in the fourth quarter worth about $336,041,000. Raymond James Financial Inc. bought a new position in IQVIA in the fourth quarter valued at approximately $236,120,000. American Century Companies Inc. boosted its holdings in shares of IQVIA by 396.0% in the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after buying an additional 905,960 shares during the period. Invesco Ltd. increased its position in shares of IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after acquiring an additional 902,226 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its holdings in shares of IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after acquiring an additional 712,958 shares during the period. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of NYSE IQV opened at $148.90 on Friday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market cap of $25.76 billion, a price-to-earnings ratio of 19.85, a P/E/G ratio of 1.99 and a beta of 1.34. The stock's fifty day moving average price is $163.91 and its two-hundred day moving average price is $188.25. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. IQVIA's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period last year, the firm earned $2.54 earnings per share. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on IQV shares. Morgan Stanley increased their target price on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. UBS Group reduced their price target on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday. Citigroup reduced their target price on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Robert W. Baird lowered their price target on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $231.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.